Vimarsana
Biggest News Aggregation in the World

Page 5 - Research Early Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Research Early Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Research Early Development Today - Breaking & Trending Today

Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-designed, Immune-modulating Drug Candidate - Vimarsana News

Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-designed, Immune-modulating Drug Candidate

First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise

Editas Medicine Announces First Quarter 2021 Results and - Vimarsana News

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicine...

Editas Medicine Announces First Quarter 2021 Results and Update - Vimarsana News

Editas Medicine Announces First Quarter 2021 Results and Update

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing nov...

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief - Vimarsana News

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development f...

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer - Vimarsana News

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer

Published: Apr 21, 2021 - Backed by leading healthcare investors including SV Health Investors - Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”). The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technolog...